African Americans could get further access to a pioneering treatment in the future to prevent HIV from collecting. The treatment,…
African Americans could get further access to a pioneering treatment in the future to prevent HIV from collecting. The treatment, called Truvada for PrEP, stops the spread of HIV in Australia, and researchers hope to test it in populations globally, according to a new study.
RELATED: Do not Believe Hype: Seven HIV / AIDS Myths We Must Stop Believing
Truvada for PrEP or Pre-Exposure Prophylaxis – A term referring to the use of antiviral drugs to help prevent HIV and AIDS – has been acclaimed as a game changer. New cases of HIV among gay and bisexual men fell by almost a third to lowest on record, according to recent research published by Australian researchers in Lancet HIV Medical Journal. New HIV infections fell from 1
49 to 102 in New South Wales, Australia in the first year after the study began – an unprecedented decline that gives a new hope to fight the virus that leads to AIDS.
Australian researchers investigated and measured the results of Truvada, an antiviral prescription drug made by Gilead Sciences Inc., which comes in the form of a blue pill, for the first time with the study.
“The rate of decline we have seen in new HIV infections among gay and bisexual men is the world’s first, says study leader Andrew Grulich, director of HIV epidemiology and prevention at Kirby Institute of University of New South Wales.” These numbers are the lowest on record since HIV surveillance began in 1985. “
HIV rates among newly infected populations worldwide dropped to 1.8 million worldwide in 2017, a decrease of more than 3 million per year in most 1990s. African Americans saw a greater proportion of new HIV diagnoses compared to other races and ethnicities. By 2016, African Americans accounted for 44 percent of HIV diagnoses, although they comprised only 12 percent of the American population, according to Centers for Disease Control and Prevention.
Truvada for PrEP , a fixed dose mixture of tenofovir, disoproxil and emtricitabine, has been used for HIV prevention. About 180,000 people in the United States two G Truvada for PrEP at the end of June, Robin L. Washington, Gilead’s Chief Financial Officer, told Bloomberg in July. Areas with the most use of PrEP saw some of the best reductions in HIV infections, “said Gilead’s CEO John F. Milligan.
It is unclear how and when researchers can further drive Truvada’s use in the United States but most likely that African Americans and other risky populations will try to take treatment.
Real Life Uncle Ruckus! Minister Jesse Lee Peterson: “Black people have been so violent over the years”
Frazzled White Woman calls the police on black children: “It’s like an uprising here!”
Original article can be found by clicking here